Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Intraocular pressure (IOP) is the most important modifiable risk factor to prevent and delay
progression of glaucoma. IOP reduction has been proven to delay the onset and progression of
glaucoma, and uncontrolled IOP is constantly associated with progression of visual field
loss.
Medical therapy is the first line in IOP reduction for Primary Open Angle Glaucoma (POAG). It
is a known fact that glaucoma patients often require addition of a second antiglaucoma
medications when disease progresses or tachyphylaxis occurs. It was reported that more than
50% of patients require 2 or more medications to achieve optimum IOP control.
Nevertheless, compliance and adherence are often impaired with multiple-drug therapy.
Combining two ocular hypotensive agents in one bottle may help patients adhere to therapeutic
regimen by reducing the number of medications used and the total number of doses
administered.